Conclusion/Relevance: CDK4/6 inhibitors are a relatively new class of drugs that are very effective in improving the response of ER breast cancer patients. There are many more aspects about them that need to be further evaluated in the clinic to allow CDK4/6 inhibitors to reach their full potential in breast cancer treatment.

Conclusion:The risk of hematological and solid cancers was higher in the patients with pSS when compared to general population. In our pSS cohort, the risk for ovarian cancer was found to be increased, which has not been previously reported in the literature.

Conclusion: RS was primarily driven by the estrogen module regardless of age, but the proliferation module had a stronger impact on RS in younger patients. The impact of modules varied in patients with different genetic and clinical risks.

From this study we can infer that elevated D-dimer and fibrinogen levels suggest a worsening of the disease, a later clinical stage, and a greater likelihood of tumor metastasis, thus both markers can be used as an auxiliary index for the staging and prognostication of breast cancer. Two recent reviews validate this position.

Moderate or high-risk BPE is related to a higher risk of breast cancer. BPE may be used as a stratification variable in interventional studies. Also, increase the use of breast MRI for breast cancer screening and diagnosis make data on BPE more available to detect the possibility of risk of breast cancer and opposing the possible negative...